FAST Feasibility Study

Inclusion Criteria:

• Subject must be at least 18 years of age
• Subject (or legal guardian) understands the study requirements and the treatmentprocedures and provides written informed consent before any study-specific tests orprocedures are performed
• Subject is eligible for percutaneous coronary intervention (PCI) and is an acceptablecandidate for coronary artery bypass grafting (CABG)
• Subject has either: Symptomatic coronary artery disease with one of the following: stenosis > 70%, abnormalfractional flow reserve (FFR), abnormal stress or imaging stress test, or elevatedbiomarkers prior to the procedure or Documented silent ischemia based on one of thefollowing: abnormal fractional flow reserve (FFR), abnormal stress or imaging stress test,or elevated biomarkers prior to the procedure
• Subject is willing to comply with all protocol-required follow-up evaluation
• Target lesion must be <12 mm in length with reference vessel diameter >2.75 mm and <3.25 mm
• Target lesion must have visually estimated stenosis >50% and <100% with thrombolysisin Myocardial Infarction (TIMI) flow >1
• The target lesion must be successfully predilated Note: Successful predilatationrefers to dilatation with a balloon catheter of appropriate length and diameter with ≤30% residual stenosis and no dissection greater than National Heart, Lung, BloodInstitute (NHLBI) type C.

Exclusion Criteria:

• Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent withacute MI
• Subjects with unstable angina or recent MI (clinically diagnosed within the past 2weeks) must have cardiac troponin (cTn) documented prior to the procedure and areexcluded if cTn is > 5x ULN
• Subject has cardiogenic shock, hemodynamic instability requiring inotropic ormechanical circulatory support, intractable ventricular arrhythmias, or ongoingintractable angina
• Non-target vessel or side branch has been treated with any type of PCI (e.g., balloonangioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to the indexprocedure
• Target vessel has been treated with any type of PCI (e.g., balloon angioplasty, stent,cutting balloon, atherectomy) within 1 year prior to the index procedure
• Planned PCI or CABG after the index procedure
• Subject has a known allergy to contrast that cannot be adequately premedicated or tothe study scaffold system or protocol-required concomitant medications (e.g.,everolimus or structurally related compounds, polymer or individual components, allP2Y12 inhibitors, or aspirin)
• Subject has received an organ transplant or is on a waiting list for an organtransplant
• Subject is receiving or scheduled to receive chemotherapy within 30 days before orafter the index procedure
• Subject has a known condition(s) of the following (as assessed prior to the indexprocedure):
• Other serious medical illness (e.g., cancer, congestive heart failure) that mayreduce life expectancy to less than 24 months
• Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.)
• Planned procedure that may cause non-compliance with the protocol or confounddata interpretation
• Subject previously treated at any time with intravascular brachytherapy
• Subject is receiving chronic (> 72 hours) anticoagulation therapy (i.e., heparin,coumadin) for indications other than acute coronary syndrome
• Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3
• Subject has a white blood cell (WBC) count <3,000 cells/mm3
• Subject has documented or suspected liver disease that is clinically significant,including laboratory evidence of active hepatitis
• Subject is on dialysis or has baseline serum creatinine level >2.0mg/dL (177µmol/L)
• Subject has a history of bleeding diathesis or coagulopathy or will refuse bloodtransfusions
• Subject has had a history of cerebrovascular accident (CVA) or transient ischemicattack (TIA) within the past 6 months
• Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding
• Subject has signs or symptoms of active heart failure (i.e., is NYHA class IV) at thetime of the index procedure
• Subject is participating in another investigational drug or device clinical study thathas not reached its primary endpoint
• Subject intends to participate in another investigational drug or device clinicalstudy within 12 months after the index procedure
• Subject is a woman of child-bearing potential with known intention to procreate within 12 months after the index procedure. (Women of child-bearing potential who aresexually active must agree to use a reliable method of contraception from the time ofscreening through 12 months after the index procedure)
• Subject is a woman who is pregnant or nursing (A pregnancy test must be performedwithin 7 days prior to the index procedure in women of child-bearing potential)
• Planned treatment of more than 1 target lesion and 1 non-target lesion (see below "Multiple Interventions During Index Procedure")
• Planned treatment of the target lesion with more than 1 scaffold
• Target lesion is located in the left main
• Target lesion is located within 3mm of the origin of the left anterior descending (LAD) coronary artery, left circumflex (LCX) coronary artery or right coronary artery (RCA)
• Target lesion is located within a saphenous vein graft or arterial graft or will beaccessed via a saphenous vein graft or an arterial graft
• Target lesion involves a side branch >2.0mm in diameter
• Target lesion involves a clinically significant side branch <2.0 mm in diameter thathas a clinically significant stenosis at the ostium.
• Target lesion and/or target vessel proximal to the target lesion is moderately toseverely calcified
• Excessive tortuosity or extreme angulation proximal to or within the target lesion
• Target lesion is restenotic from a previous stent implantation
• Thrombus, or possible thrombus, present in the target vessel
• Non-target lesion to be treated during the index procedure meets any of the followingcriteria:
• Located within the target vessel
• Located within a bypass graft (venous or arterial)
• Left main location
• Chronic total occlusion
• Involves a complex bifurcation (e.g., bifurcation lesion requiring treatment withmore than 1 stent)
• Restenotic from previous intervention
• Subject has unprotected left main coronary artery disease (>50% diameter stenosis)